Cost analysis of drug therapy in rheumatoid arthritis;Análise de custo do tratamento medicamentoso da artrite reumatóide

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 44, Issue 1, 2008, Pages 25-33

  Monteiro, Roberta Dyonísio Canaveira ^a,b   Zanini, Antonio Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Anti TNF; DMARDs; Pharmacoeconomy analysis; Rheumatoid arthritis drug therapy

Indexed keywords

HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ARTICLE; BRAZIL; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; HUMAN; OUTCOMES RESEARCH; PROBABILITY; RHEUMATOID ARTHRITIS;

EID: 46449137516     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-93322008000100004     Document Type: Article

References (20)

1. CLASSIFICAÇÃO Brasileira Hierarquizada de Procedimentos Médicos. 4.ed. São Paulo: Editera AMB, 2005. 199 p.
2. DRUMMOND, M.F.; O'BRIEN, B.J.; STODDART, G.L.; TORRANCE, G.W. Methods for the economic evaluation of health care programmes. London: Oxford Medical Publications, 1998. 200 p.
3. EMERY, P. Review of health economics modeling in rheumatoid arthritis. Pharmacoeconomics, v.22, supl.1, p.55-69, 2004.
4. GABRIEL, S.E.; TUGWELL, P.; DRUMMOND, M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann. Rheum. Dis., v.61, p.370-373, 2002.
5. GABRIEL, S.E.; COLYLE, D.; MORELAND, L.W. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics, v.19, n.7, p.715-728, 2001.
6. GUIA Farmacêutico Brasíndice. São Paulo: Andrei Publicações Médicas, 2006. 230 p.
7. LAURINDO, I.M.M.; PINHEIRO, G.R.C.; XIMENES, A.C.; BERTOLO, M.B.; XAVIER, R.M.; GIORGI, R.D.N.; CICONELLI, R.M.; RADOMINSKI, S.C.; LIMA, F.A.C.; BATISTELA, L.; ALENCAR, P. Consensu brasileiro para o diagnóstico e tratamento da artrite reumatóide. Rev. Bras. Reumatol., v.72, n.6, p.355-361, 2002.
8. LUBECK, D.P. A review of the direct costs of rheumatoid arthritis. Managed Care versus Fee-for-Service Settings. Pharmacoeconomics, v.19, n.8, p.811-818, 2001.
9. MARCH, L.; LAPSLEY, H. What are the costs to society and the potential benefits from the effective management of early rheumatoid arthritis? Bailliére's Best Prac. Res. Clin. Rheumatol., v.15, n.1, p.171-185, 2001.
10. MERKESDAL, S.; RUOF, J.; HUELSEMANN, J.L.; SCOEFFSKI, O.; MAETZEL, A.; MAU, W.; ZEIDLER, H. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J. Rheumatol., v.28, p.657-661, 2001.
11. MONTEIRO, R.D.C. Análise de custo do tratamento medicamentoso da artrite reumatóide. São Paulo, 2006. f.151. [Dissertaç ão de Mestrado. Faculdade de Ciências Farmacêuticas. Universidade de São Paulo].
12. NURMOHAMED, M.T.; DIJKMANS, B.A.C. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs, v.65, n.5, p.661-694, 2005.
13. OLLENDORF, D.A.; PETERSON, A.N.; DOYLE, J.; HUSE, D.M. Impact of leflunomida versus biologic agents on the costs of care for rheumatoid arthritis in a Managed Care population. Am. J. Manag. Care, v.8, n.7, p.S203-S213, 2002.
14. POLANEZYK, C.A.; RIBEIRO, J.P. Análise e estimativa dos custos das intervenções médicas. Estudos de Custo-Efetividade em Cardiologia: Da Teoria à Prática, São Paulo: Lemos, 1998 n.3, p 12-15.
15. SCHADLICH, P.K.; ZEIDLER, H.; ZINK, A.; GROMNICA-IHLE, E.; SCHNEIDER, M.; STRAUB, C.; BRECHT, J.G.; HUPPERTZ, E. Modeling cost effectiveness and cost utility of sequential DMARD therapy including leflunomida in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs. Pharmacoeconomics, v.23, n.4, p.377-393, 2005.
16. SCOTT, D.L. Pursuit of optimal outcomes in rheumatoid arthritis. Pharmacoeconomics, v.22, supl.1, p.13-26, 2004.
17. SCOTT, D.L.; SHIPLEY, M.; DAWSON, A.; EDWARDS, S.; SYMMONS, D.P.M.; WOOLF, A.D. The clinical management of rheumatoid arthritis and osteoarthritis strategies for improving clinical effectiveness. Br. J. Rheumatol., v.37, p.546-554, 1998.
18. SOLOMON, D.H.; AVORN, J., Pharmacoepidemiology and rheumatic diseases: 2001-2002. Curr. Opin. Rheumatol., v.15, n.2, p.122-126, 2003.
19. TUGWELL, P. Farmacoeconomia da terapia medicamentosa para artrite reumatóide. Rheumatol., v.39, supl.1, p.43-47, 2000.
20. ZANINI, A.C.; WADT, M. Farmacoeconomia. In: LOPES, A.C.; AMATO NETO, V. (Eds.) Tratado de clínica médica. São Paulo: Roca, 2006. v.1, cap.38, p.370-378.